Semaglutide Pen Injector

Phase 3

UUniversitaire Ziekenhuizen KU Leuven

Semaglutide Pen Injector is one of 13 therapeutic programs targeting Glucose intolerance. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Glucose IntoleranceRecruiting

Glucose IntolerancePhase 3

Recruiting

Competition

Competitive Landscape

17 competitors in Glucose Intolerance

#DrugCompanyPhaseTrials

Actigall

Rayos

Januvia

ZZydus Therapeutics Inc.

Aldactone

1 5

Avandia

Alnylam Pharmaceuticals

Phase 3

1 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

Trulicity

Eli Lilly

Phase 2

1 8

Mifeprex

DDanco

Phase 2

1 9

Glucophage

EMD Serono

Phase 1

1 10

Avandia

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Recruiting

Glucose Intolerance

NCT05569772

Clinical

Trials by Indication[1]

Glucose intolerance1 trial

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes: a Double Blind RCT

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 3·NCT05569772·252 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Semaglutide Pen Injector. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Semaglutide Pen Injector. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Universitaire Ziekenhuizen KU Leuven company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversitaire Ziekenhuizen KU Leuven

Semaglutide Pen Injector

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Glucose intolerance1 trial

References

Drug Info

Quick Facts

Related News